WO2001041781A2 - Inhibiteurs de proteine id pour le traitement de maladies oculaires - Google Patents

Inhibiteurs de proteine id pour le traitement de maladies oculaires Download PDF

Info

Publication number
WO2001041781A2
WO2001041781A2 PCT/US2000/032585 US0032585W WO0141781A2 WO 2001041781 A2 WO2001041781 A2 WO 2001041781A2 US 0032585 W US0032585 W US 0032585W WO 0141781 A2 WO0141781 A2 WO 0141781A2
Authority
WO
WIPO (PCT)
Prior art keywords
neovascularization
diseases
angiostatic agent
ocular
retinal
Prior art date
Application number
PCT/US2000/032585
Other languages
English (en)
Other versions
WO2001041781A3 (fr
Inventor
Abbot F. Clark
Joseph M. Defaller
Original Assignee
Alcon Universal Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd. filed Critical Alcon Universal Ltd.
Priority to AU19355/01A priority Critical patent/AU1935501A/en
Publication of WO2001041781A2 publication Critical patent/WO2001041781A2/fr
Publication of WO2001041781A3 publication Critical patent/WO2001041781A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors

Definitions

  • the present invention is directed to the use of Id-1 and Id-3 inhibitors to treat persons suffering from angiogenesis dependent ocular diseases.
  • Id inhibitor of differentiation
  • the present invention is directed to compositions and methods for treating angiogenesis dependent ocular diseases.
  • Id-1 and Id-3 inhibitors or antagonists are useful in preventing the formation of new blood vessels associated with angiogenesis dependent ocular diseases, including, but not limited to: retinal diseases (diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, age-related macular degeneration due to subretinal neovascularization); rubeosis ulceris; inflammatory diseases; chronic uveitis; neoplasms (retinoblastoma, pseudoglioma); Fuchs' heterochromic iridocyclitis; neovascular glaucoma; corneal neovascularization (inflammatory, transplantation, developmental hypoplasia of the iris); neovascularization resulting following a combined vitrectomy and lensectomy; vascular diseases (retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, carotid artery ischemia); neovascularization of the
  • the Id-1 and Id-3 inhibitors are advantageous over existing therapies (e.g.. laser photocoagulation) because they inhibit new blood vessel development without altering existing or normal blood vessel and destroying healthy tissue.
  • Laser photocoagulation destroys both existing normal blood vessel and healthy tissues while destroying the targeted new blood vessels.
  • the Id-1 and/or Id-3 inhibitors of the present invention can be drug-like, small molecules or agents that prevent Id transcription or translation.
  • the Id-1 and/or Id-3 inhibitors can be dosed by topical ocular administration, intraocular injection, subconjunctival administration, subtenons or periocular injection, systemic administration, or via an expression vector administered ocularly.
  • the Id-1 and Id-3 inhibitors can be incorporated into various types of ophthalmic formulations for delivery to the eye. These compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution.
  • Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound.
  • the ophthalmic solution may contain a viscosity enhancer, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac.
  • a viscosity enhancer such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like.
  • the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum.
  • Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-970, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
  • the compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 10.
  • the compounds will normally be contained in these formulations in an amount 0.001% to 10% by weight, but preferably in an amount of .01% to 2% by weight.
  • 1 to 4 drops of these formulations would be delivered to the surface of the eye 1 to 6 times per day according to the routine discretion of a skilled clinician.
  • the Id-1 and Id-3 proteins can also be used to discover new angiostatic agents. Recombinant Id-1 and Id-3 proteins can be used by those skilled in the art in ligand binding assays to discover agents that interact with and inhibit Id activity.
  • those skilled in the art can use cell lines expressing Id-1 and Id-3 promotors or Idl and Id-3 responsive gene promotors coupled to a reporter gene (e.g. luciferase) to discover agents that regulate Id-1 /Id-3 gene expression or Id-1 /Id-3 responsive genes.
  • a reporter gene e.g. luciferase

Abstract

Cette invention concerne des compositions et des méthodes permettant de traiter une néovascularisation oculaire avec des inhibiteurs de Id-1 ou Id-3.
PCT/US2000/032585 1999-12-09 2000-11-30 Inhibiteurs de proteine id pour le traitement de maladies oculaires WO2001041781A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19355/01A AU1935501A (en) 1999-12-09 2000-11-30 Id protein inhibitors for treating ocular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16984799P 1999-12-09 1999-12-09
US60/169,847 1999-12-09

Publications (2)

Publication Number Publication Date
WO2001041781A2 true WO2001041781A2 (fr) 2001-06-14
WO2001041781A3 WO2001041781A3 (fr) 2002-04-25

Family

ID=22617439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032585 WO2001041781A2 (fr) 1999-12-09 2000-11-30 Inhibiteurs de proteine id pour le traitement de maladies oculaires

Country Status (2)

Country Link
AU (1) AU1935501A (fr)
WO (1) WO2001041781A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000036A1 (fr) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Traitement d'anomalies du métabolisme du glucose avec un antagoniste d'inhibiteur de la différenciation 1

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371617A2 (fr) * 1988-10-31 1990-06-06 Alcon Laboratories, Inc. Utilisation de stéroides angiostatique pour l'obtention d'un médicament destiné à contrôler l'hypertension oculaire
WO1993010141A2 (fr) * 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Steroïdes angiostatiques
WO1997005283A1 (fr) * 1995-08-01 1997-02-13 Sloan-Kettering Institute For Cancer Research Id UTILISE EN TANT QUE MARQUEUR DIAGNOSTIQUE DANS DES CELLULES TUMORALES
WO1997041844A1 (fr) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinaisons de composes angiostatiques
WO1999032127A1 (fr) * 1997-12-19 1999-07-01 Alcon Laboratories, Inc. Agents angiostatiques et compositions permettant de lutter contre l'hypertension intra-oculaire
US6127178A (en) * 1998-03-20 2000-10-03 The Regents Of The University Of California Apoptotic peptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371617A2 (fr) * 1988-10-31 1990-06-06 Alcon Laboratories, Inc. Utilisation de stéroides angiostatique pour l'obtention d'un médicament destiné à contrôler l'hypertension oculaire
WO1993010141A2 (fr) * 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Steroïdes angiostatiques
WO1997005283A1 (fr) * 1995-08-01 1997-02-13 Sloan-Kettering Institute For Cancer Research Id UTILISE EN TANT QUE MARQUEUR DIAGNOSTIQUE DANS DES CELLULES TUMORALES
WO1997041844A1 (fr) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinaisons de composes angiostatiques
WO1999032127A1 (fr) * 1997-12-19 1999-07-01 Alcon Laboratories, Inc. Agents angiostatiques et compositions permettant de lutter contre l'hypertension intra-oculaire
US6127178A (en) * 1998-03-20 2000-10-03 The Regents Of The University Of California Apoptotic peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LYDEN D ET AL: "ID1 AND ID3 ARE REQUIRED FOR NEUROGENESIS, ANGIOGENESIS AND VASCULARIZATION OF TUMOUR XENOGRAFTS" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 401, 14 October 1999 (1999-10-14), pages 670-677, XP002942869 ISSN: 0028-0836 cited in the application *
ROWE P M: "New class of inhibitors for angiogenesis proposed" THE LANCET, vol. 354, 16 October 1999 (1999-10-16), page 1362 XP002187042 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000036A1 (fr) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Traitement d'anomalies du métabolisme du glucose avec un antagoniste d'inhibiteur de la différenciation 1

Also Published As

Publication number Publication date
WO2001041781A3 (fr) 2002-04-25
AU1935501A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
RU2297243C2 (ru) Ингибиторы киназы-3 гликогенсинтазы (gsk-3) для лечения глаукомы
US7625927B2 (en) Method of treating glaucoma
KR101953736B1 (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
US20140079694A1 (en) Cai-based systems and methods for the localized treatment of ocular and other diseases
JPH11504330A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
JPH02502635A (ja) 緑内障、水頭症、および脳水腫（頭蓋液量異常）治療用のアトリオペプチン、グアニル酸シクラーゼ賦活物質、およびホスホジエステラーゼ阻害物質
US5545626A (en) Method of treating glaucoma with oligonucleotides
EP1242090A1 (fr) Utilisation d'un antagoniste h1 et d'un steroide inoffensif dans le traitement des affections oculaires
EP1796675A2 (fr) Compositions et methodes de traitement de maladies ophtalmiques
KR100499903B1 (ko) 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제
RU2465898C2 (ru) Модуляторы связывания pai-1 для лечения глазных болезней
US20110105599A1 (en) Therapeutic or preventive agents for ischemic neuropathy
WO2001041781A2 (fr) Inhibiteurs de proteine id pour le traitement de maladies oculaires
US20090117098A1 (en) Complement C1Q Inhibitors For The Prevention And Treatment Of Glaucoma
WO1998024468A1 (fr) TGFα UTILISE POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME
US7867999B1 (en) Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US6534475B1 (en) Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization
Caprioli The pathogenesis and medical management of glaucoma
EP0928786B1 (fr) Inhibiteurs da la angiogenesis
EP1169026B1 (fr) Utilisation d'activateurs ap-1 pour le traitement du glaucome et de l'hypertension oculaire
KAO et al. Corneal and scleral penetration studies of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor
KR20240019817A (ko) 퇴행성 망막 질환에 사용하기 위한 trpa1 채널 길항제 화합물
WO2006053150A2 (fr) Compositions pharmaceutiques pour application topique, pour le traitement de la degenerescence maculaire liee a l'age et de l'hypertension oculaire
WO2002076460A2 (fr) Reduction de la pression intra-oculaire au moyen de propentofylline
Urtti 2 Kinetic aspects in the design of prolonged action ocular drug delivery systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP